Affordable Access

deepdyve-link
Publisher Website

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.

Authors
  • Li, Pengxiang1, 2
  • Wong, Yu-Ning3
  • Armstrong, Katrina4
  • Haas, Naomi5
  • Subedi, Prasun6
  • Davis-Cerone, Margaret6
  • Doshi, Jalpa A1, 2
  • 1 Division of General Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 2 Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania.
  • 3 Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • 4 Massachusetts General Hospital, Boston, Massachusetts.
  • 5 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • 6 Pfizer Inc., New York, New York.
Type
Published Article
Journal
Cancer Medicine
Publisher
Wiley
Publication Date
Feb 01, 2016
Volume
5
Issue
2
Pages
169–181
Identifiers
DOI: 10.1002/cam4.574
PMID: 26645975
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC patients in a real-world setting. Utilizing the 2000-2010 SEER Research files, a pre-post study design with a contemporaneous comparison group was employed to examine differences in survival outcomes for patients diagnosed with advanced RCC (study group) or advanced prostate cancer (comparison group, for whom no significant treatment innovations happened during this period) across the pretargeted therapy era (2000-2005) and the targeted therapy era (2006-2010). RCC patients diagnosed in the targeted therapy era (N = 6439) showed improved survival compared to those diagnosed in the pretargeted therapy era (N = 7231, hazard ratio (HR) for all-cause death: 0.86, P < 0.01), while the change between the pre-post periods was not significant for advanced prostate cancer patients (HR: 0.97, P = 0.08). Advanced RCC patients had significantly larger improvements in overall survival compared to advanced prostate cancer patients (z = 4.31; P < 0.01). More detailed year-to-year analysis revealed greater survival improvements for RCC in the later years of the posttargeted period. Similar results were seen for cause-specific survival. Subgroup analyses by nephrectomy status, age, and gender showed consistent findings. Patients diagnosed with advanced RCC during the targeted therapy era had better survival outcomes than those diagnosed during the pretargeted therapy era. Future studies should examine the real-world survival improvements directly associated with targeted therapies. © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times